CFRA analyst Wan Nurhayati revised the price target for Novo Nordisk (NYSE:NVO) shares, reducing it to $90 from the previous target of $122. Despite the price target cut, the analyst retained a Hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback